Form 4: Indivior Director Granted 3,722 Restricted Stock Units

Indivior Pharmaceuticals, Inc. director Stuart A. Kingsley received a grant of 3,722 Restricted Stock Units, increasing his beneficial ownership.

Summary

• Stuart A. Kingsley, a Director of Indivior Pharmaceuticals, Inc. (INDV), was granted 3,722 Restricted Stock Units (RSUs) on January 26, 2026.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• The RSUs were granted at a price of $0, which is typical for such equity compensation.
• Following this transaction, Stuart A. Kingsley beneficially owns 4,642 securities.
• The RSUs will vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the grant date, contingent on Mr. Kingsley's continued service to the Issuer.

Sentiment

Score: 7

Explanation: The filing reports a routine equity compensation grant to a director, which is a positive for aligning management interests with shareholders but does not indicate significant operational or financial news.

Positives

• The grant of Restricted Stock Units aligns the director's interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• Equity compensation is a standard practice for retaining and incentivizing key personnel, including directors.

Future Outlook

The granted Restricted Stock Units are subject to future vesting, which will occur on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the grant date, provided the reporting person continues their service to the Issuer.

Industry Context

The grant of Restricted Stock Units to a director is a common form of non-cash compensation in publicly traded companies across various industries. This practice is widely used to align the long-term interests of directors and executives with those of the company's shareholders, encouraging sustained performance and value creation.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a standard component of executive and director compensation packages in publicly traded companies, consistent with global benchmarks for corporate governance and incentive alignment.
• The $0 transaction price for RSUs is typical, as the value is derived from the underlying common stock upon vesting, rather than an upfront purchase.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with shareholder value creation, potentially leading to more focused long-term decision-making.
• Employees: No direct impact on general employees is indicated by this filing.
• Director (Stuart A. Kingsley): Receives equity compensation, incentivizing continued service and performance.

Next Steps

• The Restricted Stock Units will vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the grant date, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details a routine grant of Restricted Stock Units to a director as part of their compensation. While it aligns the director's interests with shareholders, it does not provide new information regarding the company's operational performance, financial health, or strategic direction that would alter an investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals.

Keywords

Indivior Pharmaceuticals, INDV, Stuart A. Kingsley, Form 4, Restricted Stock Units, RSU grant, beneficial ownership, director compensation, equity compensation